Inventiva Discontinues Systemic Sclerosis Drug After Mid-Stage Flop

Shares of France-based Inventiva have plunged more than 45 percent after the company reported that its experimental treatment for a rare autoimmune disease failed to hit primary and secondary endpoints in a mid-stage trial.